Network-1 Technologies, Inc. announced that ILiAD Biotechnologies, LLC reported the first-ever demonstration of protection against B. pertussis (whooping cough) colonization in a Phase 2b Human Challenge study of its BPZE1 vaccine. ILiAD announced that its BPZE1 intranasal pertussis vaccine has met the primary endpoint of protection against nasopharyngeal B. pertussis colonization (p=0.03) in the Phase 2b CHAMPION-1 Study. To date, Network-1 has invested an aggregate of $7,000,000 in ILiAD which represents approximately 6.8% of the outstanding units of ILiAD on a non-fully diluted basis.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.87 USD | -3.61% | -2.60% | -14.22% |
1st Jan change | Capi. | |
---|---|---|
-14.22% | 43.96M | |
+21.67% | 472M | |
+5.86% | 348M | |
+90.00% | 167M | |
-12.98% | 143M | |
-.--% | 139M | |
+120.54% | 86.83M | |
+13.11% | 85.8M | |
+104.95% | 69.38M |
- Stock Market
- Equities
- NTIP Stock
- News Network-1 Technologies, Inc.
- Network-1 Technologies, Inc. Reports First-Ever Demonstration of Protection Against B. Pertussis Colonization in Phase 2B Human Challenge Study of Bpzel Vaccine